Common use of NONRENEWAL OR TERMINATION Clause in Contracts

NONRENEWAL OR TERMINATION. 8.1 This Agreement shall be effective on (MONTH, DAY, YEAR) and shall continue in force until (MONTH, DAY, YEAR). 8.2 This Agreement may be terminated by either party by giving written notice to the other party at least sixty (60) days prior to the effective date of the termination. Up until the effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on Iowa’s Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th day after a party gives written notice requesting termination. 8.3 This Agreement may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “authorized governmental authority” shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department of Justice, Department of Health and Human Services) or the State of Iowa (e.g., Iowa Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC 1396r-8. 8.4 Any renewal or termination will not affect rebates due or owning on or before the effective date of termination.

NONRENEWAL OR TERMINATION. 8.1 This Agreement shall be effective on (MONTH<MM/DD/YYYY>, DAY, YEAR) and shall continue in force until (MONTH, DAY, YEAR)<MM/DD/YYYY>. 8.2 This Agreement may be terminated by either party by giving written notice to the other party at least sixty thirty (6030) days prior to the effective date of the termination. Up until the effective date of termination, the Manufacturer’s 's Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on Iowa’s Wyoming's Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s 's Covered Product(s) will be available to the Iowa Wyoming Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s 's obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th 30th day after a party gives written notice requesting termination. 8.3 This Agreement may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “"authorized governmental authority” " shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department of Justice, Department of Health and Human Services) or the State of Iowa Wyoming (e.g., Iowa Wyoming Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC 1396r-8. 8.4 Any renewal or termination will not affect rebates due or owning on or before the effective date of termination.

NONRENEWAL OR TERMINATION. 8.1 7.1 This Agreement shall be effective on (MONTHthe Effective Date and, DAYabsent early termination pursuant to the terms of this Agreement, YEAR) and shall continue in force until (MONTH, DAY, YEAR)the Termination Date. 8.2 7.2 This Agreement may be terminated terminated, in whole or in part, by either party by giving written notice to the other party as indicated: (a) During the Agreement period, if the generic equivalent of any Covered Product should become available, either party may terminate this Agreement as to such Covered Product by giving at least sixty (60) days prior notice.. (b) Either party may terminate this Agreement in whole or in part for any reason or no reason at all by providing written notice at least one hundred and eighty (180) days prior to the effective date of the termination. Termination shall become effective the 180th day after a party gives written notice requesting termination (c) In the event that the Department determines, as a result of a drug utilization therapeutic review, that a specific Covered Product of the Manufacturer or a therapeutic class of Covered Products included on the Iowa Medicaid Preferred Drug List, should require prior authorization for appropriateness of therapy based on best clinical practice standards, and the specific Covered Product is disadvantaged relative to the other preferred brand products in that class, the parties agree that written notice of termination of the agreement for the Covered Product shall be at least sixty (60) days prior to the effective date of the terminationprior authorization implementation. Up until the Termination shall become effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on Iowa’s Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th day after a party gives written notice requesting terminationauthorization implementation. 8.3 7.3 This Agreement Agreement, or a portion thereof, may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC U.S.C. § 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “authorized governmental authority” shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department of Justice, Department of Health and Human Services) or the State of Iowa (e.g., Iowa Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC U.S.C. § 1396r-8. 8.4 (c) A determination that any Covered Product is a Line Extension Drug. Termination under this subsection may be in whole or in part and may relate to certain Covered Products or to all Covered Products addressed by this Agreement. 7.4 Up until the effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way inconsistent with this Agreement. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Medicaid Program beneficiaries but may require prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. 7.5 Any renewal or termination will not affect rebates due or owning on or before the effective date of termination.

NONRENEWAL OR TERMINATION. 8.1 7.1 This Agreement shall be effective on (MONTHthe Effective Date and, DAYabsent early termination pursuant to the terms of this Agreement, YEAR) and shall continue in force until (MONTH, DAY, YEAR)the Termination Date. 8.2 7.2 This Agreement may be terminated terminated, in whole or in part, by either party by giving written notice to the other party as indicated: (a) During the Agreement period, if the generic equivalent of any Covered Product should become available, either party may terminate this Agreement as to such Covered Product by giving at least sixty (60) days prior notice.. (b) Either party may terminate this Agreement in whole or in part for any reason or no reason at all by providing written notice at least one hundred and eighty (180) days prior to the effective date of the termination. Termination shall become effective the 180th day after a party gives written notice requesting termination (c) In the event that the Department determines, as a result of a drug utilization therapeutic review, that a specific Covered Product of the Manufacturer or a therapeutic class of Covered Products included on the Iowa Medicaid Preferred Drug List, should require prior authorization for appropriateness of therapy based on best clinical practice standards, and the specific Covered Product is disadvantaged relative to the other preferred brand products in that class, the parties agree that written notice of termination of the agreement for the Covered Product shall be at least sixty (60) days prior to the effective date of the terminationprior authorization implementation. Up until the Termination shall become effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on Iowa’s Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th day after a party gives written notice requesting terminationauthorization implementation. 8.3 7.3 This Agreement Agreement, or a portion thereof, may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC U.S.C. § 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “authorized governmental authority” shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department of Justice, Department of Health and Human Services) or the State of Iowa (e.g., Iowa Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC U.S.C. § 1396r-8. Termination under this subsection may be in whole or in part and may relate to certain Covered Products or to all Covered Products addressed by this Agreement. 8.4 7.4 Up until the effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way inconsistent with this Agreement. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Medicaid Program beneficiaries but may require prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. 7.5 Any renewal or termination will not affect rebates due or owning on or before the effective date of termination.

NONRENEWAL OR TERMINATION. 8.1 This Agreement shall be effective on January 1 2010 (MONTH, DAY, YEAR) and shall continue in force until December 31 2010 (MONTH, DAY, YEAR). 8.2 This Agreement may be terminated by either party by giving written notice to the other party at least sixty thirty (6030) days prior to the effective date of the termination. Up until the effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on IowaWyoming’s Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Wyoming Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th 30th day after a party gives written notice requesting termination. 8.3 This Agreement may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “authorized governmental authority” shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department of Justice, Department of Health and Human Services) or the State of Iowa Wyoming (e.g., Iowa Wyoming Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC 1396r-8. 8.4 Any renewal or termination will not affect rebates due or owning on or before the effective date of termination.

NONRENEWAL OR TERMINATION. 8.1 This Agreement shall be effective on (MONTH, DAY, YEAR) and shall continue in force until (MONTH, DAY, YEAR). 8.2 This Agreement may be terminated terminated, in whole or in part, by either party by giving written notice to the other party as indicated: (a) During the Agreement period, if the generic equivalent of any Covered Product should become available, written notice of termination of the agreement for the covered product shall be at least sixty (60) days prior to the effective date of the termination. Termination shall become effective the 60th day after a party gives written notice of termination. (b) During the Agreement period for a Covered Product for which no generic equivalent is available, written notice of termination of the agreement for the covered product shall be at least one hundred and eighty (180) days prior to the effective date of the termination. Termination shall become effective the 180th day after a party gives written notice requesting termination. (c) In the event that the Department determines, as a result of a drug utilization therapeutic review, that a specific Covered Product of the Manufacturer or a therapeutic class of Covered Products included on the Iowa Medicaid Preferred Drug List, should require prior authorization for appropriateness of therapy based on best clinical practice standards, and the specific Covered Product is disadvantaged relative to the other preferred brand products in that class, the parties agree that written notice of termination of the agreement for the covered product shall be at least sixty (60) days prior to the effective date of the prior authorization implementation. Termination shall become effective on the effective date of the prior authorization implementation. Up until the effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on Iowa’s Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th day after a party gives written notice requesting termination. 8.3 This Agreement may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “authorized governmental authority” shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department of Justice, Department of Health and Human Services) or the State of Iowa (e.g., Iowa Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC 1396r-8. 8.4 Any renewal or termination will not affect rebates due or owning on or before the effective date of termination.

NONRENEWAL OR TERMINATION. 8.1 7.1 This Agreement shall be effective on (MONTHthe Effective Date and, DAYabsent early termination pursuant to the terms of this Agreement, YEAR) and shall continue in force until (MONTH, DAY, YEAR)the Termination Date. 8.2 7.2 This Agreement may be terminated terminated, in whole or in part, by either party by giving written notice to the other party as indicated: (a) During the Agreement period, if the generic equivalent of any Covered Product should become available, either party may terminate this Agreement as to such Covered Product by giving at least sixty (60) days prior notice. (b) Either party may terminate this Agreement in whole or in part for any reason or no reason at all by providing written notice at least one hundred and eighty (180) days prior to the effective date of the termination. Termination shall become effective the 180th day after a party gives written notice requesting termination. (c) In the event that the DOM determines, as a result of a drug utilization therapeutic review, that a specific Covered Product of the Manufacturer or a therapeutic class of Covered Products included on the Mississippi Medicaid Preferred Drug List, should require prior authorization for appropriateness of therapy based on best clinical practice standards, and the specific Covered Product is disadvantaged relative to the other preferred brand products in that class, the parties agree that written notice of termination of the agreement for the Covered Product shall be at least sixty (60) days prior to the effective date of the terminationprior authorization implementation. Up until the Termination shall become effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on Iowa’s Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th day after a party gives written notice requesting terminationauthorization implementation. 8.3 7.3 This Agreement Agreement, or a portion thereof, may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC U.S.C. § 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “authorized governmental authority” shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department Division of Medicaid Justice, Department of Health and Human Services) or the State of Iowa Mississippi (e.g., Iowa Mississippi Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC U.S.C. § 1396r-8. Termination under this subsection may be in whole or in part and may relate to certain Covered Products or to all Covered Products addressed by this Agreement. 8.4 7.4 Up until the effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way inconsistent with this Agreement. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Mississippi Medicaid Program beneficiaries but may require prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. 7.5 Any renewal or termination will not affect rebates due or owning owing on or before the effective date of termination.

NONRENEWAL OR TERMINATION. 8.1 This Agreement shall be effective on (MONTH, DAY, YEAR) and shall continue in force until (MONTH, DAY, YEAR).until 8.2 This Agreement may be terminated by either party by giving written notice to the other party at least sixty thirty (6030) days prior to the effective date of the termination. Up until the effective date of termination, the Manufacturer’s Covered Product(s) will not be discouraged or disadvantaged in any way relative to any other brand name pharmaceutical product on IowaWyoming’s Medicaid Preferred Drug List. After the effective date of the termination, the Manufacturer’s Covered Product(s) will be available to the Iowa Wyoming Medicaid Program beneficiaries only through prior authorization, and the Manufacturer’s obligation to pay State Supplemental Rebates will terminate. Termination shall become effective the 60th 30th day after a party gives written notice requesting termination. 8.3 This Agreement may be immediately terminated upon the occurrence of any one of the following events: (a) A determination by any court or any authorized governmental authority that the arrangements and transactions under this Agreement or any similar agreement constitute a violation of any law or regulation including without limitation 42 USC 1320a-7b(b) prohibiting illegal remunerations. (For the purposes of this Section, 8.3, “authorized governmental authority” shall mean any officer or agency of the Federal Government (e.g., Office of Inspector General, Department of Justice, Department of Health and Human Services) or the State of Iowa Wyoming (e.g., Iowa Wyoming Attorney General) having substantive jurisdiction over the subject matter of this Agreement; any state or federal program with which this Agreement is connected; any actions which must be taken by either party hereto in order to perform its obligations under this Agreement or any laws or regulations affecting the legality of this Agreement); or (b) A determination by CMS that the State Supplemental Rebates paid or payable by the Manufacturer under this Agreement will affect or be included in Best Price or AMP calculations for determining rebates paid pursuant to 42 USC 1396r-8. 8.4 Any renewal or termination will not affect rebates due or owning owing on or before the effective date of termination.